Principal Investigator
Delineating the molecular alterations mediating resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)
Chronic myeloid leukemia can be treated successfully by targeted therapy with tyrosine kinase inhibitors. However resistance to TKIs occurs in 10% of patients in chronic phase and 80% patients in the acute phase of blast crisis. In India patients report to clinic with advance disease. Moreover, age at onset is a decade earlier than in the western world, thus patient is on TKIs for longer period. Both of these increase the probability of developing resistance to TKIs. We aim to generate molecular profiles of CD34+ cells isolated from peripheral blood of TKI-sensitive and –resistant chronic myeloid leukemia patients in chronic as well as acute phase. Multi-omics approach has been applied to understand and integrate alterations in different macromolecules. This would help to understand the molecular basis of resistance to tyrosine kinase inhibitors in CML.
The molecular mechanism mediating expression of senescent cell antigen… more
Chronic myeloid leukemia (CML) epitomises successful targeted therapy with 90% pat… more
Chronic myeloid leukemia (CML) epitomises successful targeted therapy with 90% patients in chr… more
Despite the availability of imatinib mesylate, a targeted therapy for treatment of Chron… more
The discovery of tyrosine kinase inhibitors (TKIs) brought a major breakthrough in… more
PhD student, JRF
PhD student, JRF
Scientific Assistant 'D'
PhD student, SRF
PhD student, SRF
J Transl Med. 2019 May 31;17(1):184. doi: 10.1186/s12967-019-1937-9. / Narasimhan M, Kannan S, Chawade A, Bhattacharjee A, Govekar R. (corresponding author) J Transl Med. 2019 May 31;17(1):184. doi: 10.1186/s12967-019-1937-9(corresponding author)
Understanding quasi-apoptosis of the most numerous enucleated components of blood needs detailed molecular autopsy.Ageing Res Rev. 2017 May;35:46-62. doi: 10.1016/j.arr.2017.01.002. Epub 2017 Review.
Prognostic utility of autoantibodies to α-enolase and Hsp70 for cancer of the gingivo-buccal complex using immunoproteomics.Proteomics Clin Appl. 2013 Jun;7(5-6):392-402. doi: 10.1002/prca.201200081. Epub 2013 PMID: 23161576
Prognostic utility of autoantibodies to α-enolase and Hsp70 for cancer of the gingivo-buccal complex using immunoproteomics.Proteomics Clin Appl. 2013 Jun;7(5-6):392-402. doi: 10.1002/prca.201200081. Epub 2013 PMID: 23161576